West Pharmaceutical Services (WST) Stock Analysis & AI Equity Report
West Pharmaceutical Services (WST) overview
West Pharmaceutical Services (WST) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 3,074m and operating profit of USD 585m; the year-end share price was 275.14 USD and market capitalisation was USD 19,810m. West Pharmaceutical Services is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get West Pharmaceutical Services's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About West Pharmaceutical Services
West Pharmaceutical Services designs and produces containment and delivery systems for injectable drugs and healthcare products. Its offerings include packaging components, drug containment solutions, drug delivery devices, contract manufacturing, analytical laboratory services and integrated support. The company serves biologic, generic, pharmaceutical, diagnostic and medical device customers, providing proprietary products as well as custom design, manufacturing and assembly solutions.
Generate the West Pharmaceutical Services report
West Pharmaceutical Services is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for West Pharmaceutical Services and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on West Pharmaceutical Services
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.